PLK

Polo-like kinase (PLK) is a highly conserved serine/threonine protein kinase with a highly homologous serine/threonine kinase domain at its N-terminus, which regulates PLK activity and subcellular dynamics at the C-terminus and targeted polo-box domain (PBD). There are many PLK family members, and there are four subtypes in the human body, namely PLK1, PLK2, PLK3, and PLK4, which play important roles in the regulation of various phases of the cell cycle.

Cat. No.	Product name	CAS No.	Purity
TN3247	7-O-Prenylscopoletin	13544-37-1	98%
TN3247	7-O-Prenylscopoletin and cedrelopsin show high antiproliferative activities against cancer cell lines.
T16559	Poloxime	17302-61-3	98%
T16559	Poloxime is a hydrolysis product of poloxin and is a non-ATP-competitive Plk1 inhibitor. It also has moderate Plk1 inhibitory activity.
T21678	3MB-PP1	956025-83-5	98%
T21678	3MB-PP1 is an inhibitor of Polo-like kinase 1 (PLK1) and inhibits Leu93 Mutant Zipper-interacting protein kinase (Leu93-ZIPK) with an IC50 of 2 μM. 3MB-PP1 can b...
T2704	MLN0905	1228960-69-7
T2704	MLN0905 is an effective PLK1 inhibitor(IC50=2 nM).
T2634	Ro3280	1062243-51-9	100%
T2634	Ro3280 is an effective, specific inhibitor of PLK1(IC50=3, Kd=0.09 nM).
T16750	Rigosertib	592542-59-1	97.33%
T16750	Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer agent, which...
T10215	AAPK-25	2247919-28-2	97.79%
T10215	AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in prometaphase, followed by...
T7200	TAK-960	1137868-52-0	98%
T7200	TAK-960 is an orally bioavailable, selective inhibitor of Plks with IC50 values of 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively.
T6019	Volasertib	755038-65-4	98.04%
T6019	Volasertib (BI-6727) is a potent inhibitor of PLK1 (IC50: 0.87 nM), inducing mitotic arrest and apoptosis. It also inhibits PLK2/PLK3 (IC50s: 5/56 nM).
T6173	BI 2536	755038-02-9	98.31%
T6173	BI2536 is an effective Plk1 inhibitor (IC50: 0.83 nM). It has 4- and 11-fold greater selectivity than Plk2 and Plk3.
T22288	(1E)-CFI-400437 dihydrochloride	1247000-76-5	98.36%
T22288	CFI-400437 dihydrochloride is a selective and potent polo-like kinase 4 (PLK4) inhibitor.
T7384	CFI-400945 free base	1338806-73-7	98.53%
T7384	CFI-400945 is an potent, selective and orally active inhibitor of polo-like kinase 4(PLK4; Ki value of 0.26 nM).
T19664	ON1231320	1312471-39-8	98.69%
T19664	ON1231320 is a Polo-like kinase 2 (PLK2) inhibitor.
T14927	Centrinone	1798871-30-3	98.76%
T14927	Centrinone (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM).
T3643	HMN-176	173529-10-7	98.99%
T3643	HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1).
T2271	SBE13 Hydrochloride	1052532-15-6	99.01%
T2271	SBE13 hydrochloride is an effective and specific PLK1 inhibitor (IC50: 0.2 nM); no inhibition om Aurora A kinase, Plk2/3.
T6338	PHA-680632	398493-79-3	99.03%
T6338	PHA-680632 is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. It has 10- to 200-fold higher IC50 for FGF...
T0973	Pyridoxine	65-23-6	99.18%
T0973	Pyridoxine is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body. Although pyridoxine and vitamin B6 are still frequently us...
T16560	Poloxin	321688-88-4	99.19%
T16560	Poloxin is a non-ATP competitive Polo-like Kinase 1 inhibitor. It targets the polo-box domain (IC50: appr 4.8 μM).
T2438	HMN-214	173529-46-9	99.28%
T2438	HMN-214(IVX214) is a potent PLK1 inhibitor with an average IC50 of 0.12 μM.